Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential

Therapeutic Advances in Chronic Disease

Volumn 9, Issue 1, 2018, Pages 33-50

  Røder, Michael E ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

cardiovascular events; cardiovascular safety; glucagon like peptide 1 (GLP 1) receptor agonist; sodium glucose co transporter type 2 (SGLT2) inhibitor; type 2 diabetes

Indexed keywords

ALBIGLUTIDE; APLEWAY; CANAGLIFLOZIN; CANAGLIFLOZIN PLUS METFORMIN; DAPAGLIFLOZIN; DAPAGLIFLOZIN PLUS METFORMIN; DAPAGLIFLOZIN PLUS SAXAGLIPTIN; DEBERZA; DIPEPTIDYL PEPTIDASE IV; DULAGLUTIDE; EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS METFORMIN; ERTUGLIFLOZIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN DEGLUDEC; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; IPRAGLIFLOZIN; LIRAGLUTIDE; LIXISENATIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; METFORMIN; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SAXAGLIPTIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; SUGLAT; TOFOGLIFLOZIN; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIARRHEA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MORBIDITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETINOPATHY; REVIEW; VOMITING; WEIGHT REDUCTION;

EID: 85040318978     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622317735283     Document Type: Review

References (89)

1. Matheus AS de M, Tannus LR M, Cobas RA. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens 2013; 2013: 653789.
2. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.
3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397–1405.
4. Emdin CA, Rahimi K, Neal B. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603–615.
5. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
6. Gaede P, Vedel P, Larsen N. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393.
7. Gaede P, Lund-Andersen H, Parving H-H. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS)Group. Lancet 1998; 352: 837–853.
9. ACCORD Study Group, Gerstein HC, Miller ME. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818–828.
10. ADVANCE Collaborative Group, Patel A, MacMahon S. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
11. Duckworth W, Abraira C, Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.
12. Goldfine AB., Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092–1095.
13. Nissen SE, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471.
14. Baggio LL, Drucker DJ., Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–2157.
15. Wei Y, Mojsov S., Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219–224.
16. Pyke C, Heller RS, Kirk RK. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280–1290.
17. Sandoval DA, D’Alessio DA., Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015; 95: 513–548.
18. Knauf C, Cani PD, Perrin C. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554–3563.
19. Vahl TP, Tauchi M, Durler TS. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007; 148: 4965–4973.
20. Secher A, Jelsing J, Baquero AF. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473–4488.
21. Pannacciulli N, Bunt JC, Koska J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 2006; 84: 556–560.
22. Nauck MA, Homberger E, Siegel EG. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492–498.
23. Muscelli E, Mari A, Casolaro A. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340–1348.
24. Calanna S, Christensen M, Holst JJ. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 2013; 36: 3346–3352.
25. Calanna S, Christensen M, Holst JJ. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013; 56: 965–972.
26. Vilsbøll T, Agersø H, Krarup T. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220–224.
27. Courtney H, Nayar R, Rajeswaran C. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes Metab Syndr Obes 2017; 10: 79–87.
28. Madsbad S., Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 2016; 18: 317–332.
29. Wright EM, Loo DDF, Hirayama BA., Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733–794.
30. Kamran M, Peterson RG, Dominguez JH., Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 1997; 8: 943–948.
31. Farber SJ, Berger EY, Earle DP., Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125–129.
32. Felicetta JV, Sowers JR., Systemic hypertension in diabetes mellitus. Am J Cardiol 1988; 61: 34H–40H.
33. Santer R, Calado J., Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133–141.
34. Hummel CS, Lu C, Loo DDF. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol, Cell Physiol 2011; 300: C14-21.
35. Nauck MA., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014; 8: 1335–1380.
36. Macha S, Mattheus M, Halabi A. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014; 16: 215–222.
37. Ehrenkranz JRL, Lewis NG, Kahn CR. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31–38.
38. Abdul-Ghani MA, Norton L, DeFronzo RA., Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 2015; 309: F889–F900.
39. Vasilakou D, Karagiannis T, Athanasiadou E. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262–274.
40. Fioretto P, Giaccari A, Sesti G., Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 2015; 14: 142.
41. Schernthaner G, Gross JL, Rosenstock J. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508–2515.
42. Liakos A, Karagiannis T, Athanasiadou E. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 984–993.
43. Scheen AJ., SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf 2015; 14: 1879–1904.
44. Htike ZZ, Zaccardi F, Papamargaritis D. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19: 524–536.
45. Sivertsen J, Rosenmeier J, Holst JJ. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012; 9: 209–222.
46. Lovshin JA, Barnie A, DeAlmeida A. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015; 38: 132–139.
47. Drucker DJ., The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016; 24: 15–30.
48. Nakatani Y, Kawabe A, Matsumura M. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care 2016; 39: e22–e23.
49. Nikolaidis LA, Mankad S, Sokos GG. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–965.
50. Lønborg J, Vejlstrup N, Kelbæk H. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491–1499.
51. Sokos GG, Nikolaidis LA, Mankad S. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694–699.
52. Lepore JJ, Olson E, Demopoulos L. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 2016; 4: 559–566.
53. Margulies KB, Hernandez AF, Redfield MM. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016; 316: 500–508.
54. Cefalu WT, Leiter LA, Yoon K-H. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941–950.
55. Zinman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
56. Maliha G, Townsend RR., SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 2015; 9: 48–53.
57. Ferrannini E, Muscelli E, Frascerra S. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499–508.
58. Merovci A, Solis-Herrera C, Daniele G. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509–514.
59. Howard G, O’Leary DH, Zaccaro D. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809–1817.
60. Cherney DZ, Perkins BA, Soleymanlou N. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
61. Yale J-F, Bakris G, Cariou B. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463–473.
62. Kohan DE, Fioretto P, Tang W. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962–971.
63. Barnett AH, Mithal A, Manassie J. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 369–384.
64. Ndrepepa G, Braun S, King L. Prognostic value of uric acid in patients with type 2 diabetes mellitus and coronary artery disease. Clin Sci 2013; 124: 259–268.
65. Huang H, Huang B, Li Y. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014; 16: 15–24.
66. Bailey CJ, Gross JL, Pieters A. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223–2233.
67. Rosenstock J, Aggarwal N, Polidori D. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232–1238.
68. Monami M, Nardini C, Mannucci E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457–466.
69. Tahara A, Kurosaki E, Yokono M. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013; 715: 246–255.
70. Osorio H, Coronel I, Arellano A. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012; 2012: 542042.
71. Pfeffer MA, Claggett B, Diaz R. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247–2257.
72. Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.
73. Marso SP, Bain SC, Consoli A. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834–1844.
74. Holman RR, Bethel MA, Mentz RJ. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. Epub ahead of print 14 September 2017. DOI: 10.1056/NEJMoa1612917.
75. Mentz RJ, Bethel MA, Gustavson S. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J 2017; 187: 1–9.
76. Ferdinand KC, Botros FT, Atisso CM. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol 2016; 15: 38.
77. Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
78. Marx N, McGuire DK., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 2016; 37: 3192–3200.
79. Blau JE, Tella SH, Taylor SI. Ketoacidosis and SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. Epub ahead of print 24 July 2017. DOI: 10.1002/dmrr.2924.
80. Fralick M, Schneeweiss S, Patorno E., Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376: 2300–2302.
81. Peters AL, Buschur EO, Buse JB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687–1693.
82. Taylor SI, Blau JE, Rother KI., SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849–2852.
83. Frías JP, Guja C, Hardy E. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016; 4: 1004–1016.
84. Lundkvist P, Pereira MJ, Katsogiannos P. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab 2017; 19: 1276–1288
85. Seino Y, Yabe D, Sasaki T. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Investig. Epub ahead of print 14 May 2017. DOI: 10.1111/jdi.12694.
86. Scheen AJ., Cardiovascular outcome studies with incretin-based therapies: comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 2017; 127: 224–237.
87. Udell JA, Cavender MA, Bhatt DL. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3: 356–366.
88. Toulis KA, Hanif W, Saravanan P. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: a population-based, open cohort study. Diabetes Metab 2017; 43: 211–216.
89. Birkeland KI, Jørgensen ME, Carstensen B. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. Epub ahead of print 3 August 2017. DOI: 10.1016/S2213-8587(17)30258-9.